VetClick
Menu Menu
Login

VetClick

/ News
Friday, 5th December 2025 | 2,161 veterinary jobs online | 97 people actively seeking work | 5,628 practices registered

Veterinary Industry News

Send us your news

VMD Grants Marketing Authorisation For Syvazul® BTV3 In Great Britain

5 months ago
645 views

Posted
15th July, 2025 13h06

Author
Virbac Animal Health


Virbac is pleased to announce that Syvazul® BTV 3 has been granted a marketing authorisation in Great Britain for use in cattle and sheep, with a reduced dose in cattle.

‘León, 9 July 2025 – Syva is pleased to announce that Syvazul® BTV 3 has been granted a marketing authorisation (Vm 31592/5006) in GB, allowing its use in cattle and sheep to combat Bluetongue virus serotype 3 (BTV-3). The authorisation, effective from 3 July 2025, is valid indefinitely’.

A major update for cattle: reduced dose

A key breakthrough in this new authorisation is that the dose for cattle has been reduced from 4 ml to 2 ml, improving convenience and aligning with the latest regulatory data.

Indications and administration - cattle

For active immunisation to reduce viraemia caused by BTV-3.

Onset of immunity: 3 weeks after completing the primary vaccination course.

Dosage (intramuscular):

From 2 months of age in naïve animals, or from 3 months if born to immune dams. 

Primary vaccination: 2 doses of 2 ml, 3 weeks apart.

Indications and administration -  Sheep

For active immunisation to reduce viraemia, mortality, clinical signs and lesions caused by BTV-3. Onset of immunity: 4 weeks after completing the primary vaccination course.

Dosage (subcutaneous):

From 3 months of age.

Primary vaccination: 1 single dose of 2 ml.

Syvazul® BTV 3 is distributed through a partnership with Virbac. 

For further information, please get in touch with the Virbac technical team at [email protected] or speak to your Virbac Territory Manager.

For more information about SYVA : https://syva.es/en/ 


More from Virbac Animal Health


You might be interested in...